167 related articles for article (PubMed ID: 9589244)
1. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.
Heise T; Weyer C; Serwas A; Heinrichs S; Osinga J; Roach P; Woodworth J; Gudat U; Heinemann L
Diabetes Care; 1998 May; 21(5):800-3. PubMed ID: 9589244
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
Roach P; Woodworth JR
Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
5. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation.
Janssen MM; Casteleijn S; Devillé W; Popp-Snijders C; Roach P; Heine RJ
Diabetes Care; 1997 Dec; 20(12):1870-3. PubMed ID: 9405909
[TBL] [Abstract][Full Text] [Related]
6. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture.
Weyer C; Heise T; Heinemann L
Diabetes Care; 1997 Oct; 20(10):1612-4. PubMed ID: 9314644
[TBL] [Abstract][Full Text] [Related]
7. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
[TBL] [Abstract][Full Text] [Related]
8. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
[TBL] [Abstract][Full Text] [Related]
9. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.
Rave KM; Nosek L; de la Peña A; Seger M; Ernest CS; Heinemann L; Batycky RP; Muchmore DB
Diabetes Care; 2005 Oct; 28(10):2400-5. PubMed ID: 16186270
[TBL] [Abstract][Full Text] [Related]
10. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients.
Koivisto VA; Tuominen JA; Ebeling P
Diabetes Care; 1999 Mar; 22(3):459-62. PubMed ID: 10097929
[TBL] [Abstract][Full Text] [Related]
11. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
Li J; Wang Y; Han L; Sun X; Yu H; Yu Y
Clin Ther; 2012 Dec; 34(12):2333-8. PubMed ID: 23195963
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
[TBL] [Abstract][Full Text] [Related]
13. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes.
Korsatko S; Glettler K; Olsen KJ; Wutte A; Bock G; Koehler G; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2013 Mar; 15(3):241-5. PubMed ID: 23013357
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence of Jusline following subcutaneous administration in healthy subjects.
Al-Rubeaan KA; Al-Daghri NM; Alkharfy KM; Al-Attas OS; Hanif FS; Metias NS; Sabico SL
Int J Clin Pharmacol Ther; 2008 Jul; 46(7):382-8. PubMed ID: 18793592
[TBL] [Abstract][Full Text] [Related]
16. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
[TBL] [Abstract][Full Text] [Related]
17. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro.
Chao M; Wang W; Zhang Y; Lu X; Meng J; Ning G
Endocrine; 2010 Aug; 38(1):48-52. PubMed ID: 20960101
[TBL] [Abstract][Full Text] [Related]
19. A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes.
Roach P; Woodworth J; Gudat U; Cerimele B; Diebler F; Pein M; Dreyer M
Diabet Med; 2003 Nov; 20(11):946-52. PubMed ID: 14632722
[TBL] [Abstract][Full Text] [Related]
20. Insulin glulisine: a faster onset of action compared with insulin lispro.
Heise T; Nosek L; Spitzer H; Heinemann L; Niemöller E; Frick AD; Becker RH
Diabetes Obes Metab; 2007 Sep; 9(5):746-53. PubMed ID: 17593235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
